Pfizer said on Friday it has received an early clearance from the U.S. Federal Trade Commission for its proposed acquisition ...

U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk ...

Pfizer has received early U.S. antitrust clearance more than a week early for its proposed $7.3 billion Metsera acquisition, ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a ...

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Pfizer is suing Metsera and Novo Nordisk over Novo's $9 billion bid to acquire Metsera, arguing significant regulatory risk ...

Pfizer has filed a lawsuit against Metsera and Novo Nordisk, claiming Metsera violated its merger agreement by entertaining ...

Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US ...

Pfizer is getting its hands on a promising weight management candidate. The company's recent deal with the U.S. government eliminates a major risk. The stock's valuation looks attractive right now.

Pfizer is one of the world's largest pharmaceutical companies. It has a few material patent expirations on the horizon. It's doing what it has to do to deal with that headwind and others. The 6.7% ...